These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1376124)

  • 1. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis.
    Kantor TV; Whiteside TL; Friberg D; Buckingham RB; Medsger TA
    Arthritis Rheum; 1992 Jun; 35(6):694-9. PubMed ID: 1376124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
    Yarbrough WC; Weissler JC
    Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
    Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
    J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
    Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.
    Almeida I; Silva SV; Fonseca AR; Silva I; Vasconcelos C; Lima M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):347-69. PubMed ID: 26445774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine activated killer (LAK) cell activity in the peripheral blood lymphocytes of systemic sclerosis (SSc) patients.
    Silver RM
    Clin Exp Rheumatol; 1990; 8(5):481-6. PubMed ID: 2261708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in natural immunity during the course of HIV-1 infection.
    Brenner BG; Gryllis C; Gornitsky M; Wainberg MA
    Clin Exp Immunol; 1993 Aug; 93(2):142-8. PubMed ID: 7688673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomagnetic isolation of NK and LAK cells.
    Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T
    J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
    Whiteside TL; Wang YL; Selker RG; Herberman RB
    Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
    Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
    Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytotoxic effector cells: definition and analysis of activity.
    Ortaldo JR
    Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS.
    Brenner BG; Gornitsky M; Wainberg MA
    Clin Diagn Lab Immunol; 1994 Sep; 1(5):538-44. PubMed ID: 8556498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
    Mueller EA; Anderer FA
    Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
    Parrado A; Casares S; Rodríguez-Fernández JM
    Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
    Ballas ZK; Rasmussen W
    J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.